We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+7.08%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$809M
AUM Growth
+$404M
Cap. Flow
+$13B
Cap. Flow %
1,601.81%
Top 10 Hldgs %
38.43%
Holding
159
New
60
Increased
32
Reduced
34
Closed
31

Top Buys

Rank Stock Value
1
ISRL
Isramco Inc
ISRL
+$12.6B
2
AGN
Allergan plc
AGN
+$27.3M
3
ABBV icon
AbbVie
ABBV
+$22.4M
4
SHPG
Shire pic
SHPG
+$19.6M
5
PFE icon
Pfizer
PFE
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 57.07%
2 Technology 4.45%
3 Energy 3.1%
4 Industrials 2.68%
5 Materials 1.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VRNT
26
DELISTED
Verint Systems
VRNT
$8.42M 1.04%
297,332
+33,210
+13% +$851K
GCVRZ
27
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$7.69M 0.95%
+67,960
New +$33K
SLXP
28
CALL
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$7.58M 0.94%
48,500
+48,000
+9,600% +$6.96M
PBYI icon
29
Puma Biotechnology
PBYI
$404M
$7.23M 0.89%
30,296
+5,296
+21% +$1.09M
AMGN icon
30
Amgen
AMGN
$208B
$6.82M 0.84%
48,550
+8,550
+21% +$1.12M
ACOR
31
DELISTED
Acorda Therapeutics
ACOR
$6.75M 0.83%
1,659
+409
+33% +$1.53M
LLY icon
32
Eli Lilly
LLY
$1.02T
$6.3M 0.78%
97,100
-2,900
-3% -$184K
MDVN
33
DELISTED
MEDIVATION, INC.
MDVN
$6.24M 0.77%
126,230
-13,770
-10% -$585K
BCOM
34
DELISTED
B Communications Ltd
BCOM
$6.17M 0.76%
321,431
+79,726
+33% +$1.54M
MDAS
35
DELISTED
MEDASSETS INC COM STK (DE)
MDAS
$6.1M 0.75%
+433,889
New +$9.7M
SGEN
36
DELISTED
Seagen Inc. Common Stock
SGEN
$5.78M 0.71%
155,360
-142,440
-48% -$5.6M
DYAX
37
DELISTED
DYAX CORPORATION
DYAX
$5.24M 0.65%
517,556
-132,444
-20% -$1.28M
AAPL icon
38
Apple
AAPL
$4.54T
$5.04M 0.62%
+200,180
New +$4.91M
ITRN icon
39
Ituran Location and Control
ITRN
$1.09B
$4.86M 0.6%
+231,115
New +$5.18M
GOOG icon
40
Alphabet (Google) Class C
GOOG
$4.36T
$4.85M 0.6%
166,937
AMAG
41
DELISTED
AMAG Pharmaceuticals
AMAG
$4.79M 0.59%
+150,230
New +$3.2M
CLVS
42
DELISTED
Clovis Oncology, Inc.
CLVS
$4.63M 0.57%
101,955
-3,045
-3% -$127K
PCYC
43
DELISTED
PHARMACYCLICS INC
PCYC
$4.56M 0.56%
38,840
-11,160
-22% -$1.27M
CSX icon
44
CSX Corp
CSX
$93.4B
$4.48M 0.55%
419,025
-25,950
-6% -$268K
GSK icon
45
GSK
GSK
$104B
$4.46M 0.55%
77,680
-162,320
-68% -$9.95M
VTRS icon
46
Viatris
VTRS
$20.4B
$4.42M 0.55%
+97,100
New +$4.72M
ASPX
47
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$4.24M 0.52%
+165,074
New +$3.51M
BRCM
48
DELISTED
BROADCOM CORP CL-A
BRCM
$4.02M 0.5%
99,360
+20,240
+26% +$787K
AGTC
49
DELISTED
Applied Genetic Technologies Corporation
AGTC
$3.92M 0.48%
+210,724
New +$3.82M
NPSP
50
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$3.63M 0.45%
139,420
+90,420
+185% +$2.6M

Similar funds

Sphera Funds Management's Q3 2014 Portfolio in Review

As of Q3 2014, Sphera Funds Management held 159 positions worth $809M, up 99% from $406M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Sphera Funds Management deployed $13B of net new capital in Q3 2014, opening 60 new positions and adding to 32 existing holdings. Its largest new stake was Isramco Inc: 103,111,944 shares worth $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 74% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was GSK, an estimated $9.95M trimmed.

  • Sphera Funds Management's largest Q3 2014 buy was Isramco Inc: 103,111,944 shares worth $22.1M.
  • Sphera Funds Management added most to Shire pic in Q3 2014, an estimated $19.6M increase.
  • Sphera Funds Management's biggest Q3 2014 reduction was GSK, cutting an estimated $9.95M.
  • Sphera Funds Management fully exited Sanofi in Q3 2014, selling an estimated $12.7M.
  • Sphera Funds Management's ten largest holdings make up 38% of its $809M portfolio in Q3 2014.
  • Sphera Funds Management opened 60 new positions and closed 31 in Q3 2014.
  • Sphera Funds Management's portfolio value rose 99% quarter-over-quarter to $809M.

Based on Sphera Funds Management's 13F filing for Q3 2014, filed 13 Nov 2014.